Posted by PeterMartin on November 15, 2020, at 22:56:43
In reply to Re: Luvox for COVID, posted by linkadge on November 15, 2020, at 12:55:52
New pre-print paper out today suggests that Latuda might be able to block COVID19:
https://www.sciencedirect.com/science/article/pii/S0009261420311003?via%3Dihub
Highlights
This paper in-silico identifies multifaceted inhibitors (Lurasidone and Lurasidone exo) for SARS-CoV-2 that can act through the one drug multiple targets strategy.
Molecular Dynamics simulation study reveals a significantly strong binding affinity of Lurasidone and its derivative against multiple SARS-CoV-2 targets namely, main protease, papain-like protease, spike protein, RNA dependent RNA polymerase and helicase.
Lurasidone and Lurasidone exo possess favourable pharmacokinetic properties based on Lipinskis rule, ADMET and target prediction studies.
The unique multitargeting feature of Lurasidone and Lurasidone exo warrants further in-vitro and in-vivo experiments on SARS-CoV-2 for clinical applications.
poster:PeterMartin
thread:1112523
URL: http://www.dr-bob.org/babble/20201025/msgs/1112572.html